Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joann Vennari is active.

Publication


Featured researches published by Joann Vennari.


The Journal of Infectious Diseases | 1997

Genetic and Immunologic Characterization of Viruses Infecting MN-rgp120-Vaccinated Volunteers

Phillip W. Berman; Alane Gray; Terri Wrin; Joann Vennari; Donna J. Eastman; Gerald R. Nakamura; Donald P. Francis; Geoffrey J. Gorse; David H. Schwartz

Proviral sequences were determined and immunologic characterization was carried out for envelope glycoproteins from 7 vaccinees who became infected with human immunodeficiency virus type 1 (HIV-1), through high-risk behavior, while participating in clinical trials of MN-rgp120, a candidate HIV-1 vaccine. All 7 infections resulted from subtype B viruses; however, only 3 of the viruses possessed the MN serotype-defining V3 domain sequence, IGPGRAF, prevalent in 60%-70% of US infections. Six of the 7 viruses differed from MN-rgp120 at a neutralizing epitope in the C4 domain, and all 7 differed from MN-rgp120 at a neutralizing epitope in the V2 domain. Recombinant gp120 was prepared from each breakthrough specimen and tested for binding to a panel of neutralizing monoclonal antibodies. The results suggest that 6 of 7 breakthrough infections may be related to incomplete immunization or to infection with viruses that differed from the vaccine immunogen at important virus-neutralizing epitopes.


Biotechnology Progress | 2000

Development and Qualification of a Novel Virus Removal Filter for Cell Culture Applications

Shengjiang Liu; Mark Carroll; Raquel Iverson; Christine Valera; Joann Vennari; Kimberly Turco; Robert Piper; Robert Kiss; Herbert Lutz

Commercial bioreactors employing mammalian cell cultures to express biological or pharmaceutical products can become contaminated with adventitious viruses. The high expense of such a contamination can be reduced by passing all gases and fluids feeding the bioreactor through virus inactivation or removal steps, which act as viral barriers around the bioreactor. A novel virus barrier filter has been developed for removing viruses from serum‐free cell culture media. This filter removes the 20 nm minute virus of mice by >3 log reduction value (LRV), the 28 nm bacteriophage ΦX174 by >4.5 LRV, the mycoplasma Acholeplasma laidlawii by ≥8.8 LRV, and the bacteria Brevundimonas diminuta by ≥9.2 LRV. Robust removal occurs primarily by size exclusion as demonstrated over a wide range of feedstocks and operating conditions. The filtered media are indistinguishable from unfiltered media in growth of cells to high densities, maintenance of cell viability, and productivity in expressing protein product. Insulin and transferrin show high passage through the filter. The virus barrier filter can be autoclaved. The relatively high membrane permeability enables the use of a moderate filtration area.


Journal of Virology | 1995

Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.

Terri Wrin; Tatjana P. Loh; Joann Vennari; Hanneke Schuitemaker; Jack H. Nunberg


The Journal of Infectious Diseases | 1996

Protection of MN-rgp120-Immunized Chimpanzees from Heterologous Infection with a Primary Isolate of Human Immunodeficiency Virus Type 1

Phillip W. Berman; Krishna K. Murthy; Terri Wrin; Joann Vennari; E. Kathy Cobb; Donna J. Eastman; Mark Champe; Gerald R. Nakamura; Donna Davison; Michael F. Powell; Jeanine Bussiere; Donald P. Francis; Thomas J. Matthews; Timothy Gregory; John F. Obijeski


AIDS Research and Human Retroviruses | 1994

Development of a single-shot subunit vaccine for HIV-1

Jeffrey L. Cleland; Michael F. Powell; Amy Lim; Barrón L; Phillip W. Berman; Donna J. Eastman; Jack H. Nunberg; Terri Wrin; Joann Vennari


The Journal of Allergy and Clinical Immunology | 2001

Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization

Daniel Tumas; Betty Chan; Winifred Werther; Terri Wrin; Joann Vennari; Noelyn Desjardin; Robert L. Shields; Paula M. Jardieu


Journal of Pharmaceutical Sciences | 1998

Development of a single‐shot subunit vaccine for HIV‐1. 5. Programmable in vivo autoboost and long lasting neutralizing response

Jeffrey L. Cleland; Amy Lim; Ann L. Daugherty; Lorena Barrón; Noelyn Desjardin; Eileen T. Duenas; Donna J. Eastman; Joann Vennari; Terri Wrin; Phillip W. Berman; Krishna K. Murthy; Michael F. Powell


Journal of Pharmaceutical Sciences | 1996

Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response

Jeffrey L. Cleland; Lorena Barrón; Phillip W. Berman; Ann L. Daugherty; Tim Gregory; Amy Lim; Joann Vennari; Terri Wrin; Michael F. Powell


Journal of Pharmaceutical Sciences | 1996

Development of a Single-Shot Subunit Vaccine for HIV-1. 3. Effect of Adjuvant and Immunization Schedule on the Duration of the Humoral Immune Response to Recombinant MN gp120

Jeffrey L. Cleland; Lorena Barrón; Ann L. Daugherty; Donna J. Eastman; Charlotte R. Kensil; Amy Lim; Robert P. Weissburg; Terri Wrin; Joann Vennari; Michael F. Powell


Biologicals | 2002

Detection of minute virus of mice using real time quantitative PCR in assessment of virus clearance during the purification of Mammalian cell substrate derived biotherapeutics.

Dejin Zhan; Margaret R. Roy; Christine Valera; Jesse Cardenas; Joann Vennari; Janice W. Chen; Shengjiang Liu

Collaboration


Dive into the Joann Vennari's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Krishna K. Murthy

Texas Biomedical Research Institute

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge